Reported about 1 year ago
The US-China trade confrontation in June 10, 2024, led to adjustments in the international political and economic landscape, sparking a trend of localization in the US. Companies like Zhenghan, I-Wei, Tai Fu, and Polar Star, who have set up production bases in the US, emerged as big winners. In the wake of the US's 'Biological Security Act,' US-China biotechnology gradually decoupled, reshuffling the industry. This shift has prompted companies to invest in on-site production, showing promising future prospects for those with established facilities in the US. Tai Fu's CDMO services in the US have garnered attention and inquiries from many clients, as the company's FDA-approved facilities provide capacities for efficient drug development and market entry acceleration. I-Wei, on the other hand, acquired Magnifica in 2013, specializing in generic drugs and 505(b)2 products, and is attracting collaborations for drug development. By adopting a dual-report strategy in China and the US, I-Wei's heart-failure drug HH-001 passed GMP inspection in Jiangsu, China, and is expected to drive significant revenue growth in the upcoming quarters. Yian expanded by establishing a US subsidiary and acquiring US medical device companies, aiming to seize innovative medical device CDMO opportunities.
Source: YAHOO